ArticleJournal of translational medicine2025

Glioblastoma resistance to EGFR antibody-drug conjugate is driven by transcriptional reprogramming and TEK-induced EGFR suppression.

Mylan R Blomquist et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.